Merit Financial Group
BCRX icon

Merit Financial Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Merit Financial Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$92.3K Sell
11,085
-8,100
-42% -$76.3K ﹤0.01% 2333
2026
Q2 		$192K Buy
+19,185
New +$173K ﹤0.01% 2131
2025
Q2 		– Sell
-13,360
Closed -$100K – 1703
2025
Q1 		$100K Buy
+13,360
New +$108K ﹤0.01% 1357

Other funds holding BCRX

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Merit Financial Group's BCRX Position: Q3 2026 in Review

Merit Financial Group reduced its BioCryst Pharmaceuticals (BCRX) stake by 42% in Q3 2026, selling an estimated $76.3K and leaving 11,085 shares worth $92.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2333.

Merit Financial Group first reported a position in BCRX in Q1 2025 and has held it in 3 quarters since. The position peaked at $192K in Q2 2026. 191 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • Merit Financial Group held 11,085 shares of BioCryst Pharmaceuticals worth $92.3K as of Q3 2026.
  • Merit Financial Group sold 8,100 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $76.3K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Merit Financial Group's portfolio in Q3 2026, its #2333 holding.
  • Merit Financial Group first reported a position in BioCryst Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • Merit Financial Group's BioCryst Pharmaceuticals position peaked at $192K in Q2 2026.
  • 191 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Merit Financial Group's 13F filing for Q3 2026, filed 6 Nov 2026.